B Couderc

Summary

Affiliation: Institut Claudius Regaud
Country: France

Publications

  1. ncbi Reversible inactivation of the transcriptional function of P53 protein by farnesylation
    Bettina Couderc
    INSERM U563, Department Innovations thérapeutiques et Oncologie moléculaire, Institut Claudius Regaud and Faculté des Sciences Pharmaceutiques, Toulouse, France
    BMC Biotechnol 6:26. 2006
  2. ncbi In vivo restoration of RhoB expression leads to ovarian tumor regression
    B Couderc
    INSERM U563, CPTP, Toulouse, France
    Cancer Gene Ther 15:456-64. 2008
  3. ncbi Lens cell targetting for gene therapy of prevention of posterior capsule opacification
    F Malecaze
    INSERM U563, , UPS, , France
    Gene Ther 13:1422-9. 2006
  4. ncbi Adenovirus-mediated suicide gene transduction: feasibility in lens epithelium and in prevention of posterior capsule opacification in rabbits
    F Malecaze
    CJF INSERM 9510, CHU Purpan, Toulouse, France
    Hum Gene Ther 10:2365-72. 1999
  5. ncbi Preclinical study of an ex vivo gene therapy protocol for hepatocarcinoma
    B Lortal
    INSERM U563, CPTP, Institut Claudius Regaud, Toulouse, France
    Cancer Gene Ther 16:329-37. 2009
  6. ncbi Prevention of posterior capsule opacification by the induction of therapeutic apoptosis of residual lens cells
    F Malecaze
    INSERM U563, Department Ophtalmologie et Pathologie des épithéliums, Hopital Purpan, Toulouse, France
    Gene Ther 13:440-8. 2006
  7. ncbi Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model
    J P Delord
    Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux EA 3035 Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cedex, France
    Br J Cancer 103:61-72. 2010
  8. ncbi In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery
    M Golzio
    IPBS CNRS, Toulouse, France
    Gene Ther 14:752-9. 2007
  9. ncbi Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity
    J M Peron
    INSERM U531, Toulouse, France
    Gut 56:107-14. 2007
  10. ncbi Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors
    Victorine Douin
    Department of Innovations thérapeutiques en Oncologie, INSERM U563, Institut Claudius Regaud, 20 24 rue du Pont St Pierre, 31052 Toulouse, France
    BMC Biotechnol 4:16. 2004

Collaborators

  • E J Kremer
  • J M Peron
  • A Rafii
  • T Levade
  • P Gourdy
  • J P Delord
  • Victorine Douin
  • M Cemazar
  • F Malecaze
  • D Berg
  • M Penary
  • B Lortal
  • M Golzio
  • M Duboue
  • N H Lubsen
  • A Decha
  • B Serre
  • Victorine Douin-Echinard
  • Gilles Favre
  • Cendrine Grangeon
  • G Favre
  • F Gross
  • I Hennebelle
  • J Teissie
  • L Mazzolini
  • L Hellaudais
  • M Izard
  • A Bieth
  • J S Hoffmann
  • M J Pillaire
  • C Cazaux
  • A Paganin
  • A Ledoux
  • J-D Arnaud
  • M Titeux
  • Carine Cormary
  • Vickorine Douin-Echinard
  • F Revah
  • J Mallet
  • S Manenti
  • B Serres
  • J M Darbon
  • V Douin-Echinard
  • S de Neuville

Detail Information

Publications14

  1. ncbi Reversible inactivation of the transcriptional function of P53 protein by farnesylation
    Bettina Couderc
    INSERM U563, Department Innovations thérapeutiques et Oncologie moléculaire, Institut Claudius Regaud and Faculté des Sciences Pharmaceutiques, Toulouse, France
    BMC Biotechnol 6:26. 2006
    ..We proposed here a way to induce the death of gene modified cells upon request by acting on a pro-apoptotic protein cellular localization and on the activation of its apoptotic function...
  2. ncbi In vivo restoration of RhoB expression leads to ovarian tumor regression
    B Couderc
    INSERM U563, CPTP, Toulouse, France
    Cancer Gene Ther 15:456-64. 2008
    ..Therapeutic agents designed to correct defects of RhoB at the molecular level may thereby provide innovative treatment options for patients not responding to standard therapies...
  3. ncbi Lens cell targetting for gene therapy of prevention of posterior capsule opacification
    F Malecaze
    INSERM U563, , UPS, , France
    Gene Ther 13:1422-9. 2006
    ..Our combined approach using a lens-specific promoter and a biocompatible gel should render feasible a novel therapeutic strategy for PCO that targets the remaining lens cells...
  4. ncbi Adenovirus-mediated suicide gene transduction: feasibility in lens epithelium and in prevention of posterior capsule opacification in rabbits
    F Malecaze
    CJF INSERM 9510, CHU Purpan, Toulouse, France
    Hum Gene Ther 10:2365-72. 1999
    ..001). These results suggest that adenoviral vector-mediated transfer of HSV-tk into the proliferating lens epithelial cells is feasible and may provide a novel therapeutic strategy for PCO...
  5. ncbi Preclinical study of an ex vivo gene therapy protocol for hepatocarcinoma
    B Lortal
    INSERM U563, CPTP, Institut Claudius Regaud, Toulouse, France
    Cancer Gene Ther 16:329-37. 2009
    ..The procedure, in accordance with the French medical agency for gene therapy clinical trials, is now ready to begin a clinical trial...
  6. ncbi Prevention of posterior capsule opacification by the induction of therapeutic apoptosis of residual lens cells
    F Malecaze
    INSERM U563, Department Ophtalmologie et Pathologie des épithéliums, Hopital Purpan, Toulouse, France
    Gene Ther 13:440-8. 2006
    ..Manipulation of proapoptotic molecule expression could be a novel gene therapy approach for prevention of PCO...
  7. ncbi Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model
    J P Delord
    Laboratoire de Pharmacologie Clinique et Expérimentale des Médicaments Anticancéreux EA 3035 Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cedex, France
    Br J Cancer 103:61-72. 2010
    ..Unlike breast cancer, the prognostic role of the human epidermal growth factor receptor-2 (HER-2) in ovarian carcinoma remains controversial...
  8. ncbi In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery
    M Golzio
    IPBS CNRS, Toulouse, France
    Gene Ther 14:752-9. 2007
    ..Our study indicates that electric field can be used as an efficient method for siRNA delivery and associated gene silencing into cells of solid tumors in vivo...
  9. ncbi Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity
    J M Peron
    INSERM U531, Toulouse, France
    Gut 56:107-14. 2007
    ..1 months. This is mainly due to lack of effective treatment. Interleukin 12 (IL12) is a proinflammatory cytokine that has a potent antitumoral effect by stimulating innate and adoptive immunity...
  10. ncbi Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors
    Victorine Douin
    Department of Innovations thérapeutiques en Oncologie, INSERM U563, Institut Claudius Regaud, 20 24 rue du Pont St Pierre, 31052 Toulouse, France
    BMC Biotechnol 4:16. 2004
    ..For example, tricistronic retroviral vectors could be used to genetically modify antigen presenting cells, enabling them to express different co-stimulatory molecules known to enhance tumor cell immunogenicity...
  11. ncbi Involvement of CD70 and CD80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response
    Victorine Douin-Echinard
    , CPTP, INSERM U563, Institut Claudius Regaud, 20-24 rue du Pont St Pierre, 31052 Toulouse, France
    Int Immunol 15:359-72. 2003
    ....
  12. ncbi In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells
    Cendrine Grangeon
    , EA/UPRES 2048, Institut Claudius Regaud 20-24, rue du Pont Saint-Pierre, Toulouse Cedex 31052, France
    Cancer Gene Ther 9:282-8. 2002
    ..The injection of CD154-expressing tumor cell induced an antitumor protective response, both locally and distant from the injection site. The effect was most pronounced in MHC class I expressing TS/A tumor model...
  13. ncbi Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12
    Jean Marie Peron
    Liver Unit, Digestive Disease Federation, Clinique Dieulafoy, CHRU Purpan, France
    J Gastroenterol Hepatol 19:388-96. 2004
    ..The aim of the present study was to examine the anti-tumor effect and toxicity of intrahepatic delivery of IL-12 using an ex vivo gene therapy approach in a murine model of HCC...
  14. ncbi In vivo imaging of tumor growth after electrochemotherapy with cisplatin
    Maja Cemazar
    IPBS CNRS UMR 5089, Toulouse, France
    Biochem Biophys Res Commun 348:997-1002. 2006
    ..Ex vivo observations under a fluorescence microscope showed that eGFP was only detected on the outer layer of the tumor. No fluorescence was detected in the central part of the tumors, which were necrotic...